Infectious aspects of atherosclerosis

Inflammatory Diseases of Blood Vessels

Volumn , Issue , 2016, Pages 141-154

  Savolainen, Markku J ^a   Juvonen, Jukka ^b   Juvonen, Tatu ^a  

^a UNIVERSITY OF OULU   (Finland)

^b KAINUU CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900352670     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (81)

1. Mattila KJ, Valtonen VV, Nieminen MS, Asikainen S, Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke, Clin Infect Dis 1998; 26:719-734.
2. Kuvin JT, Kimmelstiel CD, Infectious causes of atherosclerosis, Am Heart J 1999; 137:216-226.
3. Fabricant CG, Fabricant J, Minick CR, Litrenta MM, Herpesvirus-induced atherosclerosis in chickens, Fed Proc 1983; 42:2476-2479.
4. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, Huttunen JK, Valtonen V, Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction, Lancet 1988; 2(8618):983-986.
5. Adam E, Melnick JL, Probtsfield JL, Petrie BL, Burek J, Bailey KR, McCollum CH, DeBakey ME, High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis, Lancet 1987; 2(8554):291-293.
6. Visseren FL, Bouter KP, Pon MJ, Hoekstra JB, Erkelens DW, Diepersloot RJ, Patients with diabetes mellitus and atherosclerosis: A role for cytomegalovirus? Diabetes Res Clin Pract 1997; 36:49-55.
7. Sorlie PD, Adam E, Melnick SL, Folsom A, Skelton T, Chambless LE, Barnes R, Melnick JL, Cytomegalovirus/ herpesvirus and carotid atherosclerosis: The ARIC Study, J Med Virol 1994; 42:33-37.
8. Nieto FJ, Adam E, Sorlie P, Farzadegan H, Melnick JL, Comstock GW, Szklo M, Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis, Circulation 1996; 94:922-927.
9. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE, Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis, JAMA 1989; 261 :35613566.
10. Ossewaarde JM, Feskens EJ, De Vries A, Vallinga CE, Kromhout D, Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not, Epidemiol Infect 1998; 120:93-99.
11. Adler SP, Hur JK, Wang JB, Vetrovec Gw, Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis, J Infect Dis 1998; 177:209-212.
12. Coutts WE, Davila M, Lymphogranuloma venereum as a possible cause of arteriosclerosis and other arterial conditions, J Trop Med Hyg 1945; 48:46-51.
13. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Manninen Y, Manttari M, Frick MH, Huttunen JK, Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study, Ann Intern Med 1992; 116:273-278.
14. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR, Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease, JAMA 1992; 268:68-72.
15. Mendall MA, Carrington D, Strachan D, Patel P, Molineaux N, Levi J, TooseyT, Camm AJ, Northfield TC, Chlamydia pneumoniae: Risk factors for seropositivity and association with coronary heart, J Infect 1995; 30:121-128.
16. Miettinen H, Lehto S, Saikku P, Haffner SM, Ronnemaa T, Pyorala K, Laakso M, Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and nondiabetic subjects in Finland, Eur Heart J 1996; 17:682-688.
17. Leinonen M, Linnanmaki E, Mattila K, Nieminen MS, Yaltonen Y, Leirisalo-Repo M, Saikku P, Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction, Microb Pathog 1990; 9:67-73.
18. Linnanmaki E, Leinonen M, Mattila K, Nieminen M, Yaltonen Y, Saikku P, Chlamydia pneumoniaespecific circulating immune complexes in patients with chronic coronary heart disease, Circulation 1993;87:1130-1134.
19. Pesonen E, Infection and intimal thickening: Evidence from coronary arteries in children, Em Heart J 1994; 15(suppl C):57-61.
20. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC, Relation of Helicobacter pylori infection and coronary heart disease, Br Heart J 1994; 71 :437-439.
21. Pasceri Y, Cammarota G, Patti G, Cuoco L, Gasbarrini A, Grillo RL, Fedeli G, Gasbarrini G, Maseri A, Association of virulent Helicobacter pylori strains with ischemic heart disease, Circulation 1998; 97: 1675-1679.
22. Mattila KJ, Nieminen MS, Yaltonen YY, Rasi YP, Kesaniemi YA, Syrjala SL, Jungel PS, Isoluoma M, Hietaniemi K, Jokinen MJ, Association between dental health and acute myocardial infarction, Br Med J 1989; 298:779-781.
23. Mattila K, Yaltonen YY, Nieminen M, Huttunen J, Dental infection and the risk of new coronary events: Prospective study of patients with documented coronary artery disease, C1in Infect Dis 1995; 20:588-592.
24. Zhou YF, Leon MB, Waclawiw MA, Popma 11, Yu ZX, Finkel T, Epstein SE, Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy, N Engl J Med 1996; 335:624-630.
25. Blum A, Giladi M, Weinberg M, Kaplan G, Pasternack H, Laniado S, Miller H, High anti-cytomegalovirus (CMY) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis, Am J Cardiol 1998; 81 :866-868.
26. Strachan DP, Carrington D, Mendall MA, Butland BK, Sweetnam PM, Elwood Pc, Cytomegalovirus seropositivity and incident ischaemic heart disease in the Caerphilly prospective heart disease study, Heart 1999; 81:248-251.
27. Ridker PM, Hennekens CH, Stampfer MJ, Wang F, Prospective study of Herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke, Circulation 1999; 98:27962799.
28. Strachan DP, Carrington D, Mendall MA, Ballam L, Morris J, Butland BK, Sweetnam PM, Elwood Pc, Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study, Br Med J 1999; 318: 1035-1039.
29. Ridker PM, Kundsin RE, Stampfer MJ, Poulin S, Hennekens CH, Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction, Circulation 1999; 99: 11611164.
30. Folsom AR, Nieto FJ, Sorlie P, Chambless L, and Graham DY, Helicobacter pylori seropositivity and coronary heart disease incidence, Circulation 1998; 98:845-850.
31. Benditt EP, Barrett T, McDougall JK, Viruses in the etiology of atherosclerosis, Proc NatI Acad Sci USA 1983; 80:6386-6389.
32. Melnick JL, Adam E, Debakey ME, Cytomegalovirus and atherosclerosis, Eur Heart J 1993; 14(suppl K):30-38.
33. Taylor-Robinson D, Thomas BJ, Chlamydia pneumoniae in arteries: The facts, their interpretation, and future studies, J Clin Pathol 1998; 51:793-797.
34. Danesh J, Collins R, Peto R, Chronic infections and coronary heart disease: Is there a link? Lancet 1997; 350(9075):430-436.
35. Chiu B, Viira E, Tucker W, Fong IW, Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery, Circulation 1997; 96:2144-2148.
36. Shor A, Kuo CC, Patton DL, Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques, S Afr Med J 1992; 82:158-161.
37. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT, Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries, J Infect Dis 1993; 167:841-849.
38. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP, Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old), Proc Natl Acad Sci USA 1995; 92:6911-6914.
39. Grayston JT, Kuo CC, Coulson AS, Campbell LA, Lawrence RD, Lee MJ, Strandness ED, Wang SP, Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery, Circulation 1995; 92:33973400.
40. Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karagounis LA, Woods ML, Anderson JL, Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease, JAm Coll Cardiol 1996; 27:1555-1561.
41. Jantos CA, Nesseler A, Waas W, Baumgartner W, Tillmanns H, Haberbosch W, Low prevalence of Chlamydia pneumoniae in atherectomy specimens from patients with coronary heart disease, Clin Infect Dis 1999; 28:988-992.
42. Thomas M, Wong Y, Thomas D, Ajaz M, Tsang V, Gallagher PJ, Ward ME, Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque, Circulation 1999; 99:27332736.
43. Malnick SD, Goland S, Kaftoury A, Schwarz H, Pasik S, Mashiach A, Sthoeger Z, Evaluation of carotid arterial plaques after endarterectomy for Helicobacter pylori infection, Am J Cardiol 1999; 83: 1586-1587.
44. Jackson LA, Campbell LA, Kuo CC, Rodriguez or, Lee A, Grayston JT, Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen, J Infect Dis 1997; 176:292-295.
45. Ramirez JA, Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis, The Chlamydia pneumoniae/Atherosclerosis Study Group, Ann Intern Med 1996; 125:979-982.
46. Maass M, Bartels C, Engel PM, Mamat U, Sievers HH, Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease, J Am Coil Cardiol 1998; 31 :827832.
47. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J, Rabbit model for Chlamydia pneumoniae infection, J Clin Microbiol 1997; 35:48-52.
48. Moazed TC, Kuo C, Grayston JT, Campbell LA, Murine models of Chlamydia pneumoniae infection and atherosclerosis, J Infect Dis 1997; 175:883-890.
49. Laitinen K, Laurila A, Pyhala L, Leinonen M, Saikku P, Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits, Infect Immun 1997; 65:4832-4835.
50. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, Carlquist JF, Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model, Circulation 1998; 97:633-636.
51. Libby P, Egan D, Skarlatos S, Roles of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for future research, Circulation 1997; 96:4095-4103.
52. Lopes-Virella ME Interactions between bacteriallipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease, Eur Heart J 1993; 14(suppl K): 118-124.
53. Nieminen MS, Mattila K, Valtonen V, Infection and inflammation as risk factors for myocardial infarction, Eur Heart J 1993; 14(suppl K):12-16.
54. Cook PJ, Lip GY, Infectious agents and atherosclerotic vascular disease, Q J Med 1996; 89:727-735.
55. Wick G, Scheu G, Amberger A, Kleindienst R, Xu Q, Is atherosclerosis an immunologically mediated disease? Immunol Today 1995; 16:27-33.
56. Dechend R, Maass M, Gieffers J, Dietz R, Scheidereit C, Leutz A, Gulba DC, Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-KB and induces tissue factor and PAI-I expression, A potential link to accelerated atherosclerosis, Circulation 1999; 100:13691373.
57. Beatty WL, Morrison RP, Byrne GI, Persistent chlamydiae: From cell culture to a paradigm for chlamydial pathogenesis, Microbiol Rev 1994; 58:686-699.
58. Nakano Y, Inai Y, Yamashita Y, Nagaoka S, Kusuzaki-Nagira T, Nishihara T, Okahashi N, Koga T, Molecular and immunological characterization of a 64-kDa protein of Actinobacillus actinomycetemcomitans, Oral Microbiol Immunol 1995; 10:151-159.
59. Kol A, Galina K, Sukhova, Andrew H, Lichtman, Libby P, Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-and matrix metalloproteinase expression, Circulation 1998; 98:300-307.
60. Birnie DH, Holme ER, McKay IC, Hood S, McColl KE, Hillis WS, Association between antibodies to heat shock protein 65 and coronary atherosclerosis, Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk, Eur Heart J 1998; 19:387-394.
61. XU Q, Kiechl S, Mayr M, Metzler B, Egger G, Oberhollenzer F, Willeit J, Wick G, Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis, Clinical significance determined in a follow-up study, Circulation 1999; 100:1169-1174.
62. Van Dam-Mieras MC, Bruggeman CA, Muller AD, Debie WH, Zwaal RF, Induction ofendothelial cell procoagulant activity by cytomegalovirus infection, Thromb Res 1987; 47:69-75.
63. Kaukoranta-Tolvanen SS, Laitinen K, Saikku P, Leinonen M, Chlamydia pneumoniae multiplies in human endothelial cells in vitro, Microb Pathog 1994; 16:313-319.
64. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC, Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells, Infect Immun 1996; 64:1614-1620.
65. Ward ME, The immunobiology and immunopathology of chlamydial infections, APMIS 1995; 103: 769-796.
66. Schachter J, Pathogenesis of chlamydial infections, Pathol Immunopathol Res 1989; 8:206-220.
67. Grayston JT, Wang SP, Yeh LJ, Kuo Cc, Importance of reinfection in the pathogenesis of trachoma, Rev Infect Dis 1985; 7:717-725.
68. Brade L, Nurminen M, Makela PH, Brade H, Antigenic properties of Chlamydia trachomatis lipopolysaccharide, Infect Immun 1985; 48:569-572.
69. Ingalls RR, Rice PA, Qureshi N, Takayama K, Lin JS, Golenbock DT, The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin, Infect Immun 1995; 63:3125-3130.
70. Juvonen J, Juvonen T, Laurila A, Kuusisto J, Alarakkola E, Sarkioja T et al, Can degenerative aortic valve stenosis be related to persistent Chlamydia pneumoniae infection? Ann Intern Med 1998; 128:741-744.
71. Patel P, Mendall MA, Carrington D, Strachan DP, LeathamE, Molineaux N, Levy J, Blakeston C, Seymour CA, Camm AJ, et al, Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors, Br Med J 1995; 311 :711-714.
72. Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L, Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease, Eur HeartJ 1998; 19:570-577.
73. Laurila A, Bloigu A, Nayha S, Hassi J, Leinonen M, Saikku P, Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis, Arterioscler Thromb Vasc BioI 1997; 17:2910-3913.
74. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ, Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction, Circulation 1997; 96:404-407.
75. Sinisalo J, Mattila K, Nieminen MS, Yaltonen Y, SyrjaHi M, Sundberg S, Saikku P, The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production, J Antimicrob Chemother 1998; 41:85-92.
76. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T, Randomized secondary prevention trial with azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection, The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study, Circulation 1999; 99:1540-1547.
77. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, Randomised trial of roxithromycin in nonQ-wave coronary syndromes: ROXIS Pilot Study, Lancet 1997; 350(9075):404-407.
78. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B, Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: The final report of the ROXIS study, Eur Heart J 1999; 20: 121-127.
79. Epstein SE, Zhu J, Lack of association of infectious agents with risk of future myocardial infarction and stroke, Definitive evidence disproving the infection/coronary artery disease hypothesis? Circulation 1999; 100: 1366-1368.
80. Grayston JT, Antibiotic treatment trials for secondary prevention of coronary artery disease events, Circulation 1999; 99: 1538-1539.
81. Folsom AR, Antibiotics for prevention of myocardial infarction? Not yet! JAMA 1999; 281 :461-462.